TP53突变套细胞淋巴瘤患者的治疗策略
本文综述TP53突变套细胞淋巴瘤的治疗策略。TP53突变与常规化学免疫治疗后早期疾病进展和死亡强相关,其不良预后价值高于MIPI、组织学特征、Ki-67升高及其他遗传学异常。作者综合现有数据,提出优先临床试验和早期使用细胞疗法的治疗策略。
要点
- TP53突变在常规化学免疫治疗患者中与早期进展和死亡强相关。
- TP53突变的不良预后价值高于MIPI、组织学特征、Ki-67升高及其他遗传学异常。
- 作者提出优先临床试验和早期使用细胞疗法的治疗策略。
核心结论
- TP53突变套细胞淋巴瘤患者接受化学免疫治疗及二线布鲁顿酪氨酸激酶抑制剂后预后差,亟需替代方案。
- 作者综合现有数据,提出优先临床试验和早期使用细胞疗法的治疗策略。
研究设计与样本
- 本文为综述,综合现有数据以指导TP53突变套细胞淋巴瘤高危患者的治疗决策。
主要发现
- TP53突变与接受常规化学免疫治疗患者早期疾病进展和死亡强相关。
- TP53突变的负面预后价值高于其他已确立风险指标,包括套细胞淋巴瘤国际预后指数、组织学特征、Ki-67升高及其他遗传学异常。
- TP53突变套细胞淋巴瘤患者接受化学免疫治疗及二线布鲁顿酪氨酸激酶抑制剂后预后差。
临床怎么用
- 作者提出优先临床试验和早期使用细胞疗法的治疗策略。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Mantle cell lymphoma is an uncommon subtype of lymphoma characterised by clinical and biological heterogeneity. Although most patients with mantle cell lymphoma have durable responses after chemoimmunotherapy, there is a need to prospectively identify high-risk subsets of patients for whom disease control with standard chemotherapy will be short lived. Among the available prognostic factors, TP53 mutations are uniquely informative owing to their strong association with early disease progression and death among patients receiving conventional chemoimmunotherapy, with the highest negative prognostic value compared with other established risk indicators, including the mantle cell lymphoma international prognostic index, histological features, elevated Ki-67, and other genetic lesions. The poor outcomes for patients with TP53-mutated mantle cell lymphoma receiving chemoimmunotherapy and second-line Bruton tyrosine kinase inhibitors represent an urgent need for alternative approaches. In this Review, we synthesise the available data to inform the management of this high-risk subset of patients and present a treatment strategy prioritising clinical trials and early use of cellular therapies.
引用
- Lew TE, Minson A, Dickinson M, et al. Treatment approaches for patients with TP53-mutated mantle cell lymphoma. Lancet Haematol. 2023. PMID: 36725119. doi:10.1016/S2352-3026(22)00355-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。